Hantavirus infection pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Category)
m (Bot: Removing from Primary care)
 
Line 45: Line 45:
{{WH}}
{{WH}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Disease]]
[[Category:Disease]]
[[Category:Emergency mdicine]]
[[Category:Emergency mdicine]]
[[Category:Disease]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]

Latest revision as of 21:57, 29 July 2020

Hantavirus infection Microchapters

Home

Patient Information

Hantavirus cardiopulmonary syndrome (HCPS) (patient information)
Hemorrhagic fever with renal syndrome (HFRS) (patient information)

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hantavirus infection from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future Investigational Therapies

Case Studies

Case #1

Hantavirus infection pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hantavirus infection pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hantavirus infection pathophysiology

CDC on Hantavirus infection pathophysiology

Hantavirus infection pathophysiology in the news

Blogs on Hantavirus infection pathophysiology

Directions to Hospitals Treating Hantavirus pulmonary syndrome

Risk calculators and risk factors for Hantavirus infection pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Hantavirus is usually transmitted via the inhalation of aerosolized viral antigens or rodent bites. The incubation period of hantavirus infection is of 9 to 33 days. Following inhalation, the virus replicates in pulmonary macrophages and dendritic cells. The primary target cells of hantavirus infection are endothelial cells of capillaries. Infection is followed by impairment of the barrier function of endothelial cells, fluid extravasation, and subsequent organ failure.

Pathophysiology

Reservoir

Each Hantavirus species is associated with a specific rodent in a given geographic region. Rodent subfamilies associated with hantaviruses include

  • Arvicolinae (Europe)
  • Murinae (Europe and Asia)
  • Sigmodontinae (Americas)

Transmission

Hantavirus is usually transmitted via the inhalation of aerosolized viral antigens or rodent bites. Human to human transmission is seen in American Hantaviruses species (Andes virus).

Incubation period

The incubation period of hantavirus infection is of 9 to 33 days.[1]

Seeding

Following inhalation, the virus replicates in pulmonary macrophages and dendritic cells.

Pathogenesis

The pathogenesis of hantavirus infection can be described by impairment of the barrier function of endothelial cells, fluid extravasation and subsequent organ failure.[2]

Impairment of the barrier function of endothelial cells

  • The primary target cells of hantavirus infection are endothelial cells of capillaries. Most commonly endothelial cells of lungs and heart are involved.
  • Hantaviruses attach to beta-3 integrin receptors of endothelial cells and stimulate T cells.[3][4]
  • Neutralizing antibody (NAbs) are produced as a result of stimulation and beta-3 integrins are inactivated.
  • Inactivation of virus-bound beta-3-integrins contributes to deregulation of vascular endothelial growth factor receptor-2 (VEGFR2) and diminished antagonism of vascular endothelial growth factor (VEGFA).[5]
  • This leads to impairment of vascular endothelial (VE) cadherin expression and subsequent loss of endothelial barrier function.
  • Platelets are consumed in high number in response to the damage to the endothelial layer resulting in thrombocytopenia.

Fluid extravasation

  • Neutralizing antibody (NAbs) also inhibit innate type I interferon (IFN) responses of endothelial cells.
  • This results in inhibition of upregulation of CD73 by IFN-beta on endothelial cells and promotes vascular leakage.

Multiorgan failure

  • Hantaviruses demonstrated to have an immunoreceptor tyrosine-based activation motif (ITAM) on their G1 envelope glycoproteins.
  • Immunoreceptor tyrosine-based activation motif along with local T-cell cytokine production results in cellular downstream and immune cell dysfunction.[6]
  • Attachment of hantavirus to beta-2 integrin receptors on neutrophils also induces the release of neutrophil extracellular traps.
  • Sensitized mononuclear cells infiltrate the lung, myocardial interstitium, and spleen to produce cytokines, particularly TNF-alpha and interferon-gamma, resulting in pulmonary edema and myocarditis

References

  1. "Incubation Period of Hantavirus Cardiopulmonary Syndrome - Volume 12, Number 8—August 2006 - Emerging Infectious Disease journal - CDC".
  2. Spiropoulou CF, Srikiatkhachorn A (2013). "The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome". Virulence. 4 (6): 525–36. doi:10.4161/viru.25569. PMC 5359750. PMID 23841977.
  3. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER (1998). "beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure". Proc. Natl. Acad. Sci. U.S.A. 95 (12): 7074–9. PMC 22743. PMID 9618541.
  4. Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER (2002). "Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration". Arch. Virol. 147 (10): 1913–31. doi:10.1007/s00705-002-0852-0. PMID 12376753.
  5. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER (2002). "Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses". Proc. Natl. Acad. Sci. U.S.A. 99 (21): 13837–42. doi:10.1073/pnas.192298899. PMC 129784. PMID 12368479.
  6. Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, Waite DC, Koster FT, Ennis FA (1999). "High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome". J. Infect. Dis. 179 (2): 295–302. doi:10.1086/314597. PMID 9878011.

Template:WH Template:WikiDoc Sources